Ask AI
ProCE Banner Activity

Phase III ALPINE Long-Term Extension Study of Zanabrutinib in Patients With Relapsed or Refractory CLL/SLL

Conference Coverage
Slideset

With 6 years of follow-up, zanubrutinib continues to demonstrate durable efficacy and a sustained progression-free survival benefit, with no new safety signals, in patients with relapsed/refractory CLL/SLL.

Released: December 19, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals caring for patients with relapsed/refractory CLL globally.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with relapsed/refractory CLL

  • Appraise the potential clinical implications of new data on novel targeted and cellular therapies for treatment selection and sequencing in patients with relapsed/refractory CLL

  • Support effective shared decision-making through patient education and resources on the potential clinical implications of recently presented data for relapsed/refractory CLL